SG11201407878VA - Therapeutic agent or prophylactic agent for dementia - Google Patents
Therapeutic agent or prophylactic agent for dementiaInfo
- Publication number
- SG11201407878VA SG11201407878VA SG11201407878VA SG11201407878VA SG11201407878VA SG 11201407878V A SG11201407878V A SG 11201407878VA SG 11201407878V A SG11201407878V A SG 11201407878VA SG 11201407878V A SG11201407878V A SG 11201407878VA SG 11201407878V A SG11201407878V A SG 11201407878VA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- tokyo
- dementia
- osaka
- llll
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
(i2) mwu ft iz s-5 iv x m £ titz s issaj n d9) mm IHMMi (43) m&'&m a 2013^12^ 5 0(05.12.2013) WIPOIPCT (10) WO 2013/180238 A1 (51) A61K39/395 (2006.01) A61P 25/28 (2006.01) C07K16/18 (2006.01) (21) (22) (25) (26) s In: C12N15/02 (2006.01) C12P 21/08 (2006.01) C07K16/46 (2006.01) PCT/JP2013/065090 2013 ^ 5 M 30 0(30.05.2013) 0*lg (30) fiBfefix — £: 2012-124336 2012 ^ 5 .E 31 0(31.05.2012) JP (71) miA: lA^&AABRrfTilA^ (OSAKA CITY UNIVERSITY) [JP/JP]; T 5588585 AEfcJfrAE* TfTlici g 3 § 1 3 8-^ Osaka (JP).'S' A 7 y — ^^5C^tt(TEIJIN PHARMA LIMITED) [JP/JP]; T 1000013 2§ 1 Tokyo (JP). (72) ^ ^(MORI, Hiroshi); T5458585 AlKJtt ABfcTtm^rE JIH7-T g 4 # 3 '&SD&- /i A A BR rfT tL A ^ l*l_ Osaka (JP). g Hi ft H (TOMIYAMA, Takami); T 5458585 AlKJtt AlKrfT j®! fSiFEJiSBr-Tg 4#3-^ ^aA^AABR rfT tL A ^ fa Osaka (JP). \'k % — (MAT- SUMOTO, Yoichi); T 1910065 0 SrrfT E3T g 3 # 2 5Jf^-t2 >J* — fa Tokyo (JP). ?IP JA (EGUCHI, Hiroshi); T 1910065 ^5iiR0S?rtrJii^HraTg 3 mm ?ifA7 7--7tt3c^a £ —fa Tokyo (JP). AS — (KUNORI, Yuichi); T 1910065 ^5liR0S?rtTjli^HraTg 3 # 2 ^ Tokyo (JP). (74) '('t IM A : W ^ H , ^1- (AOKI, Atsushi et al.); T 1058423 KifvtlUSEtft/P^HT g 5 # 1 J % /P^37i FJT Tokyo (JP). (8i) Jt^ia (^ro&i^psy > IS ^ pj f I): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) *!£H (asrofci^isy > ±T(Dmm(Dfcm% V&tf nlfb): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), n. — V [&£%] (54) Title: THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA = (54) I 00 m CJ o 00 i-H en i-H o CJ o & m (1-UTrialStJB AA iV.T j 40 W) 30 CC 20 10 3 4 (0 §)DD EE non Tg vs Tg : p=0.0071 FF Tg vs Iirmunized Tg : p=0.0029 GG AA (1-1) Trial Experiment BB Time until arrival at hidden platform CC Seconds DD Day EE Significant difference FF Non-Tg vs. Tg: p 0.0071 = GG Tg vs. Immunized Tg: p = 0.0029 -Tg+pSer413 -Tg+PBS ••nonTg+PBS (57) Abstract: The present invention provides a novel therapeutic agent or prophylactic agent for dementia. The present invention provides a therapeutic agent, prophylactic agent, or the like for dementia that contains substance a such as the following as an active ingredient: antibodies that specifically ex hibit an antigen-antibody reaction to tau proteins of which the area around Serf 13 of SEQ ID NO: 1 is phosphorylated; and peptides of which the area around Serf 13 phosphorylated. is (57)®$: \"t\"-5> >- <t <fc-5> 0 fflE^y#\"^- 1©Se r 4 1 3J! fofclfoZ?&&&•$>> S e r 4 1 3Jia^'J £JS&-f<g>0 WO 2013/180238 A11 lllll llllllll II llllll III lllll lllll lllll III III III lllll lllll llll llll lllll lllll lllllll llll llll T (AM, AZ, BY, KG, KZ, RU, TJ, TM), 3 — • V / ^ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, _ GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI — (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (&&£ 21 &(3)) (StfJJ 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 | ||
| PCT/JP2013/065090 WO2013180238A1 (en) | 2012-05-31 | 2013-05-30 | Therapeutic agent or prophylactic agent for dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407878VA true SG11201407878VA (en) | 2015-01-29 |
Family
ID=49673425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201805410XA SG10201805410XA (en) | 2012-05-31 | 2013-05-30 | Therapeutic agent or prophylactic agent for dementia |
| SG11201407878VA SG11201407878VA (en) | 2012-05-31 | 2013-05-30 | Therapeutic agent or prophylactic agent for dementia |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201805410XA SG10201805410XA (en) | 2012-05-31 | 2013-05-30 | Therapeutic agent or prophylactic agent for dementia |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (en) |
| EP (2) | EP3662931B1 (en) |
| JP (3) | JP5971659B2 (en) |
| KR (2) | KR102133610B1 (en) |
| CN (1) | CN104602708B (en) |
| AR (1) | AR091218A1 (en) |
| AU (2) | AU2013268364B2 (en) |
| BR (1) | BR112014029566A2 (en) |
| CA (1) | CA2875205C (en) |
| CY (1) | CY1122530T1 (en) |
| DK (1) | DK2857039T3 (en) |
| ES (1) | ES2763361T3 (en) |
| HK (1) | HK1210031A1 (en) |
| HR (1) | HRP20192267T1 (en) |
| HU (1) | HUE046919T2 (en) |
| IL (1) | IL235899B (en) |
| LT (1) | LT2857039T (en) |
| ME (1) | ME03587B (en) |
| MX (1) | MX361128B (en) |
| MY (1) | MY172458A (en) |
| NZ (1) | NZ630536A (en) |
| PH (1) | PH12014502669B1 (en) |
| PL (1) | PL2857039T3 (en) |
| PT (1) | PT2857039T (en) |
| RS (1) | RS59802B1 (en) |
| RU (1) | RU2657438C2 (en) |
| SG (2) | SG10201805410XA (en) |
| SI (1) | SI2857039T1 (en) |
| TW (2) | TWI777183B (en) |
| WO (1) | WO2013180238A1 (en) |
| ZA (1) | ZA201409186B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2670434B1 (en) | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
| WO2012162179A1 (en) * | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| HUE046919T2 (en) * | 2012-05-31 | 2020-04-28 | Univ Osaka City | Therapeutic agent or prophylactic agent for dementia |
| WO2014008404A1 (en) | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
| TW202136296A (en) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| EP3448875A4 (en) * | 2016-04-29 | 2020-04-08 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP6785372B2 (en) * | 2016-09-30 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | SPR-based double bond assay for functional analysis of multispecific molecules |
| MX2019009817A (en) | 2017-02-17 | 2019-11-21 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof. |
| JP2018139530A (en) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
| IL270971B1 (en) | 2017-05-30 | 2024-02-01 | Teijin Pharma Ltd | Anti-igf-i receptor antibody |
| WO2019070492A1 (en) | 2017-10-02 | 2019-04-11 | Merck Sharp & Dohme Corp. | Chromane monobactam compounds for the treatment of bacterial infections |
| CA3077247A1 (en) | 2017-10-16 | 2019-04-25 | Eisai R & D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| WO2019194314A1 (en) | 2018-04-06 | 2019-10-10 | 帝人ファーマ株式会社 | Spns2 neutralizing antibody |
| JP7340794B2 (en) * | 2018-07-04 | 2023-09-08 | 学校法人 愛知医科大学 | Antisense oligonucleotides that control tau splicing and their uses |
| CN110028583B (en) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | anti-Tau antibody and application thereof in treating Alzheimer disease and traumatic brain injury |
| JP7429404B2 (en) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | Method for producing tau-related disease models |
| US20220365102A1 (en) | 2019-09-30 | 2022-11-17 | Nipro Corporation | Tau protein detection method using blood sample as test specimen |
| JP2023518281A (en) * | 2020-03-19 | 2023-04-28 | ヴァスキュラー バイオサイエンスィズ | CAR peptides for improving coronavirus survival |
| CA3183835A1 (en) | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (en) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | arc |
| JP3587390B2 (en) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | Phosphorylated amino acid derivative and phosphorylated peptide synthesis method |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| KR20090019864A (en) * | 2006-06-16 | 2009-02-25 | 엔비보 파마슈티칼즈, 인코퍼레이티드 | Transgenic flies expressing tau and amyloid precursor |
| UA107571C2 (en) * | 2009-04-03 | 2015-01-26 | PHARMACEUTICAL COMPOSITION | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EA032675B1 (en) * | 2009-06-10 | 2019-07-31 | Нью-Йорк Юниверсити | Method and compositions for treating alzheimer's disease and other tauopathies |
| EP2670434B1 (en) * | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
| TR201102696U (en) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Freestanding moving product advertising stand. |
| HUE046919T2 (en) * | 2012-05-31 | 2020-04-28 | Univ Osaka City | Therapeutic agent or prophylactic agent for dementia |
-
2013
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/en unknown
- 2013-05-30 TW TW109121902A patent/TWI777183B/en active
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/en active IP Right Grant
- 2013-05-30 PL PL13797290T patent/PL2857039T3/en unknown
- 2013-05-30 RS RS20191640A patent/RS59802B1/en unknown
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/en active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/en active
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 SI SI201331636T patent/SI2857039T1/en unknown
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 AR ARP130101907 patent/AR091218A1/en active IP Right Grant
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/en active IP Right Grant
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 ES ES13797290T patent/ES2763361T3/en active Active
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/en active
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 MX MX2014014187A patent/MX361128B/en active IP Right Grant
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/en not_active Application Discontinuation
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/en unknown
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/en active Application Filing
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/en unknown
- 2013-05-30 TW TW102119176A patent/TWI700296B/en active
- 2013-05-30 PT PT137972907T patent/PT2857039T/en unknown
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/en active Active
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2015
- 2015-11-03 HK HK15110820.8A patent/HK1210031A1/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/en active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/en active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/en unknown
- 2019-12-17 HR HRP20192267TT patent/HRP20192267T1/en unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407878VA (en) | Therapeutic agent or prophylactic agent for dementia | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201811590RA (en) | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | |
| SG11201811193TA (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201811719RA (en) | Conjugates for targeted cell surface editing | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201407917PA (en) | Highly efficient method for establishing artificial pluripotent stem cell | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201810018TA (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
| SG11201408511QA (en) | Liquid preparations of amines and organic acids stabilized by salts | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201406913VA (en) | Text mining system, text mining method, and program | |
| SG11201807336RA (en) | Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds |